Tonix Pharma Reports Third Quarter 2016 Financial Results
NEW YORK, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq:TNXP) (Tonix), which is developing a next-generation treatment for PTSD, announced financial results for the third quarter ended September 30, 2016.
“Tonix undertook significant changes in the third quarter,” said Seth Lederman, M.D., president and chief executive officer of Tonix. “We shifted our clinical development strategy to focus resources on our promising PTSD program following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Positive data from AtEase – a 12-week randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating TNX-102 SL*, 5.6 mg, in military-related PTSD – bolstered our enthusiasm for moving forward with this therapy. We plan to initiate the HONOR study, a 12-week Phase 3 trial evaluating TNX-102 SL, 5.6 mg, in military-related PTSD, in the first quarter of the coming year.”
“Tonix undertook significant changes in the third quarter,” said Seth Lederman, M.D., president and chief executive officer of Tonix. “We shifted our clinical development strategy to focus resources on our promising PTSD program following a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). Positive data from AtEase – a 12-week randomized, double-blind, placebo-controlled Phase 2 clinical study evaluating TNX-102 SL*, 5.6 mg, in military-related PTSD – bolstered our enthusiasm for moving forward with this therapy. We plan to initiate the HONOR study, a 12-week Phase 3 trial evaluating TNX-102 SL, 5.6 mg, in military-related PTSD, in the first quarter of the coming year.”